Ivoximab and temozolomide for recurring brain tumors
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs—ivoximab (a new immunotherapy) and temozolomide (chemotherapy)—to treat gliomas (brain tumors) that have come back or stopped responding to prior treatment. The goal is to see if this combination is safe and effective.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a glioma (brain tumor) that has come back or is no longer responding to previous treatment, confirmed by biopsy and imaging
- You are in good overall health with an ECOG score of 0–1 (able to do most daily activities)
- You are expected to live at least 6 months
- Your organ function (liver, kidney, blood counts) meets minimum requirements
- You have not had immunotherapy drugs (anti-PD-1, anti-PD-L1, or similar) before
- You can swallow pills and do not have bowel obstruction
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of two drugs, bortezomib and temozolomide, for people whose brain tumor (glioblastoma) has returned after initial treatment. It's designed for tumors that don't respond well to standard treatments, and the goal is to see if this combination can help control the cancer.
This trial tests a combination of three drugs—trimipramine (an antidepressant), atezolizumab (an immunotherapy), and bevacizumab (a targeted therapy)—in people whose glioblastoma has come back after initial treatment. The goal is to see if this mix can help shrink the tumor or slow its growth.
This trial tests a new drug called ivonescimab for people whose glioblastoma has come back after standard treatment. The goal is to see if this drug can help shrink the tumor or slow its growth.
This trial studies whether combining three medicines can slow or shrink recurrent glioma (a type of brain tumor). It is for adults whose tumor has come back after standard treatment, with certain genetic tumor markers that may help guide whether you can join.
This trial tests a combination of two drugs—vebreltinib and temozolomide—for people with a type of brain cancer called glioblastoma. It is for those who have already had surgery to remove as much of the tumor as possible.
This Phase 1 study tests the safety and early effectiveness of BEY1107 combined with temozolomide in adults whose glioblastoma has come back or kept growing after standard treatment. If you qualify, you may be able to receive this combination while the researchers closely monitor side effects and tumor response.
Hear when a new Relapsed/Refractory Glioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.